<DOC>
	<DOCNO>NCT02338570</DOCNO>
	<brief_summary>Evaluation unfavourable outcome-related factor patient affect renal cell cancer treatment everolimus previously treat Vascular endothelial growth factor ( VEGF ) inhibitor ( i.e . sunitinib , sorafenib , pazopanib , bevacizumab+interferon )</brief_summary>
	<brief_title>Outcome-related Factors Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus ( ORCHIDEE )</brief_title>
	<detailed_description>Predictive factor consider : histology , Heng risk group , Eastern Cooperative Oncology Group-performance status ( ECOG-PS ) , site metastasis , glycemia cholesterolemia . The data collect `` real life '' population could contribute identify clinical factor predict favourable outcome patient treat everolimus failure first-line treatment VEGF inhibitor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Male female , age 18 year old , histologically cytologically confirm mRCC ( clear cell clear cell ) ; 2 . ECOGPS 012 ; 3 . With target and/or nontarget lesion accord Response Evaluation Criteria In Solid Tumours ( RECIST ) 1.1 ; 4 . Following failure previous treatment VEGFtargeted therapy ( e.g . sunitinib , sorafenib , pazopanib , bevacizumab+interferon ) ; 5 . For decision take initiate everolimus treatment patient currently receive treatment everolimus period time ≤30 day ; 6 . Willing able comply followup protocol requirement able commence treatment within 21 day ; 7 . Written inform consent obtain screening procedure accord local guideline . Patients meet follow criterion exclude study entry : 1 . Previous treatment everolimus date write informed consent provision receive everolimus 30 day ; 2 . Symptomatic central nervous system metastasis . Patients may eligible central nervous system metastases adequately treat ( surgery radiotherapy ) , require ongoing corticosteroid control symptoms evidence progression least three month ; 3 . Other malignancy diagnose within last 5 year , except follow , adequately treat : superficial squamous cell carcinoma basal cell carcinoma skin , superficial bladder cancer ( T1 G1 T1 G2 ) , stage 1 cervical cancer ; 4 . Treatment investigational agent past 4 week ; 5 . Clinically relevant human immunodeficiency virus , hepatitis B virus , hepatitis C virus infection ; 6 . Non adequate liver function show : serum plasma ALT AST &gt; 3.0x upper limit normal ( ULN ) &gt; 5 hepatic metastasis present ; Serum plasma total bilirubin : &gt; 1.5xULN ( except patient Gilbert 's syndrome ) ; 7 . Non adequate renal function show serum creatinine &gt; 2.5xULN ; 8 . Any follow last year : myocardial infarction , severe/ unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack pulmonary embolism ; 9 . Ongoing grade ≥2 cardiac dysrhythmias , atrial fibrillation grade prolongation correct QT interval &gt; 450 msec male &gt; 470 msec female ; 10 . Pregnancy ( negative pregnancy test require woman childbearing potential ) , breast feeding ; 11 . Inadequate contraception . Women must postmenopausal , surgically sterile , use reliable form contraception . Men must surgically sterile use barrier method contraception ; 12 . Known allergy hypersensitivity everolimus excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>